Romidepsin inhibits Ras-dependent growth transformation of NIH 3T3 fibroblasts and RIE-1 epithelial cells independently of Ras signaling inhibition.
BACKGROUND
Despite intensive effort, currently no effective anti-Ras therapies have successfully reached clinical application. Previous studies suggest that the histone deacetylatse (HDAC) inhibitor romidepsin, which is currently in clinical trials for the treatment of multiple malignancies, can block Ras-dependent signaling and growth transformation. These studies suggest that mutational activation of Ras may be a useful biomarker for sensitivity to romidepsin and that the anti-tumor activity of this HDAC inhibitor may involve inhibition of Ras effector-mediated signaling.


RESULTS
To rigorously assess romidepsin as an antagonist of Ras, we utilized two well-characterized cell models for Ras transformation. We found that romidepsin blocked the anchorage-dependent and -independent growth of NIH 3T3 fibroblasts and RIE-1 epithelial cells transformed by all three Ras isoforms. However, romidepsin treatment also blocked growth transformation caused by other oncoproteins (B-Raf and ErbB2/Neu), suggesting that romidepsin is not selective for Ras. We also observed striking differences in romidepsin-mediated growth inhibition between transformed NIH 3T3 fibroblasts compared to RIE-1 epithelial cells, suggesting that the mechanism by which romidepsin blocks transformation is dependent on cellular context. Finally, we found that romidepsin did not inhibit Ras activation of the ERK and AKT effector pathways in NIH 3T3 and RIE-1 cells, suggesting that romidepsin does not directly antagonize Ras.


CONCLUSIONS
Taken together, our results suggest that romidepsin is not selective for Ras-transformed cells and that the anti-tumor activity of romidepsin is not due to direct inhibition of Ras function.
Hanker
Ariella B
AB
Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. cjder@med.unc.edu.
Healy
Kevin D
KD
Nichols
Jean
J
Der
Channing J
CJ
Nat Rev Cancer. 2001 Dec;1(3):194-202
11902574
Exp Cell Res. 1998 May 25;241(1):126-33
9633520
Oncogene. 2006 Jan 26;25(4):512-24
16186804
Mol Cancer Ther. 2007 Mar;6(3):1099-111
17363503
Cancer J. 2007 Mar-Apr;13(2):105-13
17476138
Cancer Biol Ther. 2002 Nov-Dec;1(6):599-606
12642680
Biosci Biotechnol Biochem. 1994 Sep;58(9):1579-83
7765477
Semin Cancer Biol. 2004 Apr;14(2):105-14
15018894
Mol Cancer Res. 2003 Dec;1(14):1077-88
14707291
Mol Cell Biol. 1996 Jul;16(7):3923-33
8668210
Cell. 2000 Jan 7;100(1):57-70
10647931
Cancer Res. 2008 Sep 15;68(18):7561-9
18794144
Trends Cell Biol. 2000 Apr;10(4):147-54
10740269
Methods Enzymol. 2000;325:425-41
11036624
Cancer Res. 2007 Sep 15;67(18):8477-85
17875686
Mol Cell Biol. 2002 Apr;22(7):2304-17
11884615
Cancer Res. 2003 Nov 15;63(22):7807-14
14633707
J Natl Cancer Inst. 2002 Apr 3;94(7):504-13
11929951
Methods Enzymol. 2008;439:53-72
18374156
Nat Rev Cancer. 2003 Jan;3(1):11-22
12509763
Cancer Res. 2007 May 15;67(10):4834-42
17510413
Trends Cell Biol. 2004 Nov;14(11):639-47
15519853
J Biol Chem. 2000 Dec 29;275(52):40916-24
11007784
Nature. 2007 Oct 25;449(7165):1073-7
17960246
Biochem Biophys Res Commun. 2004 Sep 17;322(2):557-64
15325266
Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):6924-8
8692920
Nat Rev Cancer. 2003 Jun;3(6):459-65
12778136
J Biol Chem. 1996 Apr 5;271(14):7992-8
8626480
Mol Cell Biol. 2001 Aug;21(16):5488-99
11463831
Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1638-42
15668389
Cancer Cell. 2004 Aug;6(2):171-83
15324700
Br J Cancer. 2004 Jul 19;91(2):355-8
15188009
Cell Mol Immunol. 2007 Oct;4(5):337-43
17976313
Methods Enzymol. 1994;238:277-94
7799794
J Antibiot (Tokyo). 1994 Mar;47(3):301-10
7513682
FEBS Lett. 2005 Jan 3;579(1):90-4
15620695
Nat Genet. 2008 May;40(5):600-8
18372904
Cancer Chemother Pharmacol. 2006 Nov;58(5):711-5
16435156
Methods Enzymol. 1995;255:395-412
8524126
Nat Rev Drug Discov. 2006 Jan;5(1):37-50
16485345
J Pharmacol Exp Ther. 2002 Mar;300(3):890-9
11861795
Clin Exp Metastasis. 2008;25(2):183-9
18058245
Biochem Pharmacol. 2007 Sep 1;74(5):659-71
17498667
J Cancer Res Clin Oncol. 2007 Oct;133(10):725-39
17487507